Sector
PharmaceuticalsOpen
₹98.55Prev. Close
₹102.4Turnover(Lac.)
₹9.3Day's High
₹101.95Day's Low
₹98.5552 Week's High
₹11452 Week's Low
₹82.1Book Value
₹51.75Face Value
₹10Mkt Cap (₹ Cr.)
76.5P/E
13.71EPS
7.47Divi. Yield
021 Jul 2023
12:00 AM
BookCloser
24 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
21 Jul 2023
12:00 AM
AGM
Announcement Date: 21 Jul, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 7.53 | 7.53 | 7.53 | 7.53 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 25.89 | 22.1 | 16.86 | 12.73 |
Net Worth | 33.42 | 29.63 | 24.39 | 20.26 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 161.1 | 122.67 | 95.69 | 64.44 |
yoy growth (%) | 31.33 | 28.18 | 48.48 | -14.74 |
Raw materials | -130.45 | -96.58 | -76.67 | -49.27 |
As % of sales | 80.97 | 78.73 | 80.11 | 76.45 |
Employee costs | -4.95 | -3.94 | -3.44 | -2.66 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 7.02 | 5.7 | 2.28 | 1.31 |
Depreciation | -1.69 | -1.22 | -1.16 | -0.98 |
Tax paid | -1.77 | -1.57 | -0.28 | -0.48 |
Working capital | -5.22 | 7.07 | 3.56 | 1.95 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 31.33 | 28.18 | 48.48 | -14.74 |
Op profit growth | 14.88 | 62.82 | 49.37 | -22.62 |
EBIT growth | 9.49 | 73.34 | 39.35 | -28.47 |
Net profit growth | 27.06 | 106.32 | 141.23 | -54.15 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.45 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,520.1 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.15 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.6 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,639.05 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Mukund Kakani
Non-Exec. & Independent Dir.
S A Hussain
Whole Time Director & CFO
Mohit Jaju
Non-Exec. & Independent Dir.
Ramesh Babu Telugu
Non-Exec. & Independent Dir.
Vimala B Madon
Chairman (Non-Executive)
Ghanshyam Jaju
Non Executive Director
Mahindra Uday Bhalerao
Company Sec. & Compli. Officer
Venkatesh Achanta
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Godavari Drugs Ltd
Summary
Godavari Drugs Limited is engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates, through its manufacturing facility at Nanded, Maharashtra, India.. Sulphamethoxazole (SMX), the main product of the company, is a widely used anti-bacterial drug enjoying good export demand. The Company incorporated in December, 1987, has multiple production blocks for APIs, drug intermediates and fine chemicals. The company has expanded its SMX capacity from 540 tpa to 720 tpa, integrating backward into the manufacture of drug intermediates, sulphamethoxide (cap.: 450 tpa) and diethyl oxalate, DEO (cap.: 750 tpa), and diversifying into the manufacture of trimetroprim, TMP (cap.: 144 tpa).The diversification into TMP is beneficial as SMX and TMP are used in combination to treat a wide variety of infections. The backward integration into SMO and DEO will enhance value-addition. In fact, Siris and Chemox Chemicals, both having good capacities of SMX, have recently gone in for the production of SMO. In 2000 the company introduced Pyrazyamide in the market. Since the product is being well accepted in the market the company is planning to increase the capacity of Pyrazyamide of 180 TPA and have also finalised on other products Cislactum,which is a intermediate used to produce Diltiazem an anti anginal drug.The Company combine their intrinsic strengths in chemistry with capabilities of process development, right from laboratory scale topilot scale in p
Read More
What is the Godavari Drugs Ltd share price today?
The Godavari Drugs Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹101.6 today.
What is the Market Cap of Godavari Drugs Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Godavari Drugs Ltd is ₹76.50 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Godavari Drugs Ltd?
The PE and PB ratios of Godavari Drugs Ltd is 13.71 and 1.98 as of 22 Jul ‘24
What is the 52 Week High and Low of Godavari Drugs Ltd?
The 52-week high/low is the highest and lowest price at which a Godavari Drugs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Godavari Drugs Ltd is ₹82.1 and ₹114 as of 22 Jul ‘24
What is the CAGR of Godavari Drugs Ltd?
Godavari Drugs Ltd's CAGR for 5 Years at 39.62%, 3 Years at 9.92%, 1 Year at 9.04%, 6 Month at -0.26%, 3 Month at 3.42% and 1 Month at 2.74%.
What is the shareholding pattern of Godavari Drugs Ltd?
The shareholding pattern of Godavari Drugs Ltd is as follows:
Promoters - 53.16 %
Institutions - 0.50 %
Public - 46.34 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
